Published:
03/15/2024
An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of the body’s own immune cells to recognize and attack melanoma cells. In this webinar, hosted by Samantha Guild, JD, President of AIM at Melanoma, we explore the implications of this newly approved treatment for melanoma care with our guest, Dr. Allison Betof Warner, MD, PhD, a leading expert in TIL therapy.
CLICK on the image below to watch
Recent Posts
Apr. 16, 2024
Navigating the Journey Together – Conversations with Melanoma Caregivers
Apr. 12, 2024
May is Brain Tumor Awareness Month
Apr. 11, 2024
President’s Letter | April 2024
Apr. 11, 2024
Celebrating a Milestone: 20 Years of the Dallas Steps Against Melanoma Walk
Apr. 11, 2024